



In Vitro Testing of Aerosolized Substances with Primary 3D Human Airway Epithelia: Application of ALICE-Cloud Technology to e-liquids (e-cigarettes)

S. Constant¹, A. Stelzl^{2,3}, O. Eickelberg^{2,3,4}, O. Schmid^{2,3}

¹Epithelix, Genève, Switzerland

²Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany ³Institute of Lung Biology and Disease, Helmholtz Zentrum München, Munich/Neuherberg, Germany ⁴University Hospital of the Ludwig Maximilians University (LMU), Munich, Germany





Conclusions/Summary

- ALICE-Cloud technology: Easy to use, commercially available system (Vitrocell Systems, Germany) for aerosolized delivery of liquids to cells cultured at the air-liquid interface (ALI)
- Combined with primary ALI 3D cell cultures Physiologically more realistic lung model than submerged cell systems
- \succ Closed system, small enough to be operated under clean bench conditions
- Efficient drug deposition on bottom plate of ALICE-CLOUD: 0.90±0.074
- \succ Due to limited cell coverage in multi-well plate: ~6.5% cell-delivered dose
- \succ Cell delivered dose rate: 1.5 µl per insert per exposure
- \succ Time for performing one complete cell exposure: ~ 5-7 min (200µl liquid)
- Even very high eLiquids doses (~ smoking of 500, 1500 and 6000 e-cigarettes within 7 min) had almost no adverse effects on human primary bronchial epithelial cells in terms of tissue integrity, celia beating frequency, mucin secretion and IL-8 secretion.



German Research Center for Environmental Health